Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00483184) enrolled a total of 84 participants across three groups: Group 1 had 27 people, Group 2 had 31 people, and Group 3 had 26 people. The trial was measuring responses related to oral ulcers (mouth sores), specifically looking at whether participants experienced a meaningful and lasting reduction in the number of ulcers over time. By the end of the study, 72 of the 84 participants completed the trial — 22 in Group 1, 27 in Group 2, and 23 in Group 3. The reported data shows that the main (primary) outcome measured how many participants in each group achieved a "sustained response," which the trial defined as a 75% or greater reduction in total oral ulcer count across at least three consecutive visits. According to the results reported on ClinicalTrials.gov, 13 participants in Group 1, 10 in Group 2, and 12 in Group 3 met this definition of sustained response. For the secondary outcomes — which were listed as including time to first response, recurrence of ulcers, time to recurrence, pain linked to mouth sores, general wellbeing, and safety — the reported data does not include any numerical results, so those figures cannot be described here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 19717547) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male, or a female who is not pregnant and not breastfeeding.
- You have been diagnosed with Behçet's Disease and meet the recognised international diagnostic criteria for this condition.
- You have had mouth ulcers related to Behçet's Disease for at least 12 months.
- You have a history of getting multiple mouth ulcers every month.
- You currently have at least 2 mouth ulcers that can be measured, with a combined size of at least 4 mm across.
- You are willing and able to follow all study procedures and attend all required visits.
- You have signed the study consent form after it has been approved by an ethics review board.
- You have completed all required screening tests and have been accepted as suitable for the study.
Who may not be able to join:
- You have a serious ongoing or long-term illness other than Behçet's Disease, such as heart failure, liver failure, kidney failure, lupus, ulcerative colitis, cancer, leukaemia, diabetes, AIDS, or any condition that weakens your immune system.
- You are currently receiving dental treatment that would require several dentist visits during the study, or you have a mouth condition unrelated to Behçet's Disease that a dentist thinks will need treatment during the study.
- You have another medical condition (other than Behçet's Disease) that is known to cause mouth ulcers, such as Crohn's disease, lupus, or AIDS.
- You have an eating disorder and/or a mental health condition that requires treatment.
- You have had an allergic reaction to interferon-alpha in the past.
- You are a female who is pregnant, breastfeeding, or able to become pregnant but not using a medically approved form of contraception throughout the study.
- You have previously received any interferon therapy given by injection.
- You have taken interferon-alpha lozenges within the last 30 days before screening.
- You have taken thalidomide within the last 30 days before screening.
- You have taken methotrexate within the last 30 days before screening.
- You have taken any medication that suppresses the immune system within the last 30 days before screening.
- You have any disease or condition that, in the study doctor's opinion, could put you at greater risk during the trial (confirm with trial site).
- You have any abnormal blood or other laboratory test results that, in the study doctor's opinion, could put you at greater risk during the trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.